CLINICAL_TRIALS
trial_result
· 2023-08-14
Clinical Trial Update: Evaluation of NanoDoce® in Participants With Urothelial Carcinoma [Phase 1, Phase 2]
Summary
Phase 1/2 trial investigating NanoDoce® in urothelial carcinoma and bladder cancer has completed; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: NanOlogy, LLC | Conditions: Bladder Cancer, Urothelial Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-08-14